Acquired Company

Double Point Ventures acquired Lumos Pharma on December 12, 2024, via a cash tender offer of $4.25 per share plus a contingent value right per share, with Lumos Pharma continuing as a standalone business of the acquirer from its Austin, Texas headquarters.

Show more

Pharmaceutical Preparation Manufacturing

Manufacturing

Start AI Chat

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$4.34

Open

$4.34

Volume

N/A

Day Range

$4.34 - $4.34

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

32.69%

Institutional Own.

24.27%

Qtr Updated

09/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
LUM-201 (Ibutamoren) Details Pediatric growth hormone deficiency	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LUM-201 (Ibutamoren) Details Turner syndrome	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.